Navigation Links
FDA Cleared New Application for Simbionix PROcedure Rehearsal Studio
Date:2/23/2012

CLEVELAND, February 23, 2012 /PRNewswire/ --

Simbionix USA Corporation, the world's leading provider of medical education and simulation training, is pleased to announce that Simbionix received FDA clearance for the EVAR (Endovascular Aneurysm Repair) application for the PROcedure Rehearsal Studio™ (PRS). Last year Simbionix received clearance for the PRS Carotid Intervention application.

     (Logo: http://www.newscom.com/cgi-bin/prnh/20120214/511292)

 

The PROcedure Rehearsal Studio transforms the patient's CT scan into a 3D visualization model. Simbionix has developed a revolutionary technology to use this 3D visualization model within its endovascular simulator, the ANGIO Mentor, to allow surgeons to evaluate endovascular surgical treatment options before surgery. PRS provides a 3D model of the patient's vasculature and true-to-life vessel measurement tools.

After exporting the 3D model into the ANGIO Mentor simulator practice environment, the physician is able to train and practice aneurysm repair on the patient's specific anatomy. For the first time, surgeons can practice endovascular abdominal aortic aneurysm repair, including precise deployment of the bifurcated and contralateral leg stent graft, deployment of iliac and aortic extensions and touch-up ballooning.

According to Dr. Yael Friedman, Director of Regulatory Affairs for Simbionix, the Simbionix track record in advanced medical education and training is unmatched, with more than 140 studies documenting the effectiveness and value of Simbionix medical simulators. "Based on this foundation, and on quality control, development, and production processes that were put in place over the past few years, we are pleased to be able to move beyond training and also provide the market with a clinical tool," Dr. Friedman said. "We are very proud that the FDA has cleared the EVAR application and continues to recognize the clinical component of the PROcedure Rehearsal Studio."

About Simbionix USA Corporation

Simbionix is the world's leading provider of simulation, training and education products for medical professionals and the healthcare industry. The company is committed to delivering high quality products, advancing clinical performance and optimizing procedural outcomes.


Visit: http://www.simbionix.com  
Contact: Rebecca Levy, Manager of Marketing Communications, at rebecca@simbionix.com

+1-216-229-2040 Ext 128


'/>"/>
SOURCE Simbionix USA Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbotts Genetic Test for Acute Myeloid Leukemia Prognosis Cleared by FDA
2. Mesoblast Cleared to Begin First Phase 2 Clinical Trial for Eye Diseases
3. NeuroQuant®, CorTechs Labs FDA-Cleared System for Quantifying Regional Brain Atrophy from MRIs, Used to Identify Patients at Highest Risk for Developing Dementia
4. Masimo rainbow Acoustic Monitoring Technology Cleared for Market in Japan
5. New FDA-Cleared Sensititre® AIM™ Automated Inoculation Delivery System Provides Faster, Accurate Dosing of MIC Plates for Microbiology Laboratories
6. Rapid Fire Marketing: Medical Cannabis Management Cleared for Medical Cannabis Cultivation
7. Breakthrough CardioHealth® Station Cleared By FDA to Take Center Stage at the Annual Scientific Sessions of the American College of Cardiology 2011
8. Glenveigh Medical and Monica Healthcare Announce Distribution Agreement for Groundbreaking FDA Cleared Wireless Fetal Monitoring System
9. Mobile MIM, First FDA-Cleared Diagnostic Medical Imaging App, Now Available on the U.S. App Store
10. Luminex Corporation Launches New FDA Cleared Pharmacogenetic Diagnostic Test
11. Zargis to Launch FDA-Cleared Lung Sounds Analysis Technology from Stethographics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... Research and Markets has announced the addition of the "Global ... ... market to grow at a CAGR of 6.83% during the period ... growth prospects of the global travel vaccines market for 2016-2020. To ... the sales of various vaccines administered to actively immunize meningococcal disease, ...
(Date:12/9/2016)... 2016  Axovant Sciences Ltd. (NYSE: ... on the treatment of dementia, today announced a ... 2b trial evaluating treatment with intepirdine (RVT-101), combined ... plus placebo in people with mild-to-moderate Alzheimer,s disease. ... to treatment was associated with reduced progression in ...
(Date:12/8/2016)... , Dec. 8, 2016 IRIDEX Corporation (NASDAQ: ... newly issued shares of common stock, $0.01 par value (the ... underwritten public offering.  The final terms of the Offering will ... pricing, and there can be no assurance as to whether ... expects to use the net proceeds it will receive from ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... Russ ... announced the first national #QuackGivesBack campaign which supported local breast cancer organizations during ... franchise-wide Quack Gives Back initiative, and we’re very pleased with the ...
(Date:12/8/2016)... ... 08, 2016 , ... Mirixa Corporation , a leading ... pharmacist-delivered patient care services, has announced the promotions of Karen Litsinger to senior ... of sales. , Litsinger joined Mirixa in 2008 after serving as a ...
(Date:12/8/2016)... ... ... David J. Dykeman , Ginger Pigott , and J. Rick ... West, Dec. 12, 2016, at the Fairmont Newport Beach in California. Greenberg Traurig is ... Sciences & Medical Technology Group have been featured speakers at every DeviceTalks conference since ...
(Date:12/8/2016)... , ... December 08, 2016 ... ... Suite 10.2 version gives development continuity to its innovative Unified Instance Manager ... management capacity. In addition, this new version optimizes the unattended auto-dialing system ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... STAT courier ... to be a convenient service for Texas, they are expanding their presence in Dallas. ... a hiring spree that will bring new jobs to the Dallas and Forth Worth ...
Breaking Medicine News(10 mins):